‘We Want You To Stay,’ EU Agency Heads Tell UK
The role of the UK drug regulator in the EU post-Brexit will depend on the outcome of complex negotiations. It’s clear that the loss of the MHRA from the network would be keenly felt by other agencies across Europe.
You may also be interested in...
UK industry figures have outlined the importance of continuing regulatory alignment in the life sciences area after Brexit, following the latest meeting of the UK EU Life Sciences Steering Group. The UK government may be listening, but what positions will the other 27 member states take?
The extent of the UK medicines regulator’s involvement in the European regulatory network shows how complicated disentangling the UK from the system would be.
Parliament may get to vote on the terms of the UK’s departure from the EU if an important legal decision handed down today is upheld. Industry has its eye on ongoing talks with the government.